The data on biological therapies on Airway remodeling (AR) in severe asthma require further studies. The American Thoracic Society recommends future research focus on AR in asthma and improving drugs, available and future monoclonal antibodies, targeting AR. AR and chronic inflammation contribute to the symptomatology of asthma. New treatments for patients with severe asthma include monoclonal antibodies aimed at inflammatory cytokines involved in asthma pathogenesis. While the clinical data for biological therapies shows reduction of exacerbation rates, improving lung function, quality of life, and asthma control there is insufficient data on the effects of biological therapies on AR for long-term asthma management. This study reviews the data on the effects of monoclonal antibodies, primarily omalizumab while other therapies included mepolizumab, benralizumab, and tralokinumab, in asthma on AR.
- Business of Medicine
- Doctor’s Voice